NewAmsterdam Pharma Company N.V.
NAMSNASDAQHealthcareBiotechnology
As of Oct 23, 2026 close
- Market cap
- $2.43B
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $19.58$42.21
- Volume (live)
- -
- Avg. volume (3M)
- 1.64M
NewAmsterdam Pharma Company (NAMS) Stock Price & Financial Analysis
NewAmsterdam Pharma Company Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $19.13 - $21.39 |
|---|---|
| 52-Week High | $42.21 |
| 52-Week Low | $19.58 |
| Open | $21.39 |
| Volume (last close) | 2.31M |
| Average Volume (3M) | 1.64M |
| Revenue (TTM) | 7.12M |
|---|---|
| Net Income (TTM) | -259.50M |
| Free Cash Flow (TTM) | -143.72M |
| EPS (TTM) | −$2.17 |
| Profit Margin | -3644.21% |
| Operating Margin | -3432.20% |
| Return on Equity (ROE) | -41.10% |
| Debt to Equity | 0.00 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Market Cap | 2.43B |
|---|---|
| Shares Outstanding | 123.37M |
| Price to Sales (P/S) | 341.47 |
| Price to Book (P/B) | 3.85 |
| EV/EBITDA | -8.78 |
| 50-Day MA | $23.96 |
|---|---|
| 200-Day MA | $30.33 |
| 1-Year Change | −40.53% |
Source: Market prices and company fundamentals. Data as of Oct 23, 2026. Data sources and methodology
NewAmsterdam Pharma Company at a Glance
As of the Oct 23, 2026 close, NewAmsterdam Pharma Company (NAMS) has a market capitalization of $2.43B. The stock trades at 341.5× sales. Over the trailing twelve months it lost $259.50M on revenue of $7.12M and burned $143.72M of free cash flow. Revenue fell 88.9% year over year.
As of its latest reported balance sheet, it holds $424.15M in cash and securities against $82.00K of debt, a net cash position of $424.07M.
NewAmsterdam Pharma Company does not currently pay a dividend.
The share price is down 40.5% over the past year. At $19.71 (the Oct 23, 2026 close) it sits near the bottom of its 52-week range of $19.58 to $42.20, below its 200-day moving average of $30.33.
Based on 12 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $53.20, 169.9% above the Oct 23, 2026 close.
Frequently Asked Questions About NewAmsterdam Pharma Company
What is the current stock price for NAMS?
As of the Oct 23, 2026 close, NAMS stock trades at $19.71. The 52-week range is $19.58–$42.21, with a day range of $19.13–$21.39.
What is the P/E ratio for NAMS?
The P/E ratio (Price-to-Earnings) for NAMS is shown in the Key Statistics section. This valuation metric helps compare NewAmsterdam Pharma Company N.V. to industry peers.
Does NAMS pay dividends?
NewAmsterdam Pharma Company does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for NAMS?
Based on ratings from 12 professional analysts over the last 90 days, the consensus for NAMS is Buy. The average 12-month price target is $53.20, a 169.9% upside from the Oct 23, 2026 close of $19.71.
What is the market cap of NAMS?
As of the Oct 23, 2026 close, NewAmsterdam Pharma Company's market capitalization is $2.43B, classifying it as a mid-cap company. NewAmsterdam Pharma Company operates in the Healthcare sector within the Biotechnology industry.